Skip to main content
. Author manuscript; available in PMC: 2015 Jun 28.
Published in final edited form as: Cancer Lett. 2014 Mar 21;348(0):156–166. doi: 10.1016/j.canlet.2014.03.016

Figure 1. Caspase-8 activation is required for the combination of TRAIL and triptolide to induce cell death. Pancreatic cancer cells were treated with either TRAIL or triptolide or a combination of both for 24h.

Figure 1

A. Caspase-8 cleavage was detected in MIA PaCa-2 and S2-VP10 cells by western blot. β-actin expression was used as loading control.

B. Treatment with specific caspase-8 inhibitor (Z-IETD-FMK, 40μM) in MIA PaCa-2 cells results in a significant decrease in caspase-8 activity (left panel) and increase in viability (right panel) when treated with a combination of TRAIL and triptolide. The bars represent mean ± SEM, n≥3. **p< 0.01.

C. MIA PaCa-2 cells treated with caspase-8 siRNA show a significant decrease of caspase-8 expression and increase in viability when treated with a combination of TRAIL and triptolide. The bars represent mean ± SEM, n≥3. **p< 0.01.

D. PARP and caspase-3 cleavage was assessed in MIA PaCa-2 and S2-VP10 cells using western blots. β-actin expression was used as loading control.